Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eftilagimod alfa + BMS-936559
- Development stage
- Discontinued
- Lead developer
- Immutep
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Eftilagimod alfa + BMS-936559 is an investigational combination immunotherapy consisting of eftilagimod alfa (efti, formerly IMP321) and BMS-936559 (formerly MDX-1105). Eftilagimod alfa is a soluble LAG-3 fusion protein that acts as an MHC class II agonist, activating antigen-presenting cells (APCs) to trigger a sustained T-cell immune response. BMS-936559 is a fully human monoclonal IgG4 antibody that targets and blocks programmed death-ligand 1 (PD-L1), preventing its interaction with PD-1 and B7-1 to restore T-cell activity. The combination is covered under patents held by Immutep for treating cancer or infection, though it has not been evaluated in clinical trials.
- Other names
- efti + BMS-936559eftilagimod alfa + MDX-1105IMP-321 + BMS-936559IMP321 + BMS-936559IMP321 + MDX-1105
02
Targets
Beyond the preview
Go deeper on eftilagimod alfa + BMS-936559.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eftilagimod alfa + BMS-936559.
Work on eftilagimod alfa + BMS-936559? Claim this page to correct or add information. Claim this page